For repair of damaged DNA, cells increase de novo synthesis of deoxyribonucleotide triphosphates through the rate-limiting, p53-regulated ribonucleotide reductase (RNR) enzyme. In this study we investigated whether pharmacological inhibition of RNR by 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) enhanced chemoradiation sensitivity through a mechanism involving sustained DNA damage. RNR inactivation by 3-AP and resulting chemoradiosensitization were evaluated in human cervical (CaSki, C33-a) cancer cells through study of DNA damage (c-H2AX signal) by flow cytometry, RNR subunit p53R2 and p21 protein steady-state levels by Western blot analysis and laser scanning imaging cytometry, and cell survival by colony formation assays. 3-AP treatment led to sustained radiation-and cisplatin-induced DNA damage (i.e. increased c-H2AX signal) in both cell lines through a mechanism of inhibited RNR activity. Radiation, cisplatin and 3-AP exposure resulted in significantly elevated numbers and persistence of c-H2AX foci that were associated with reduced clonogenic survival. DNA damage was associated with a rise in p53R2 but not p21 protein levels 6 h after treatment with radiation and/or cisplatin plus 3-AP. We conclude that blockage of RNR activity by 3-AP impairs DNA damage responses that rely on deoxyribonucleotide production and thereby may substantially increase chemoradiosensitivity of human cervical cancers. g 2010 by Radiation Research Society INTRODUCTION Ribonucleotide reductase (RNR) catalyzes the conversion of ribonucleotide diphosphates to 29-deoxyribonucleotides (dNDPs) for DNA synthesis and repair (1, 2) . Mammalian RNR is a tetrameric enzyme of two active-site 90-kDa subunits (RNR-R1) and two 45-kDa subunits (RNR-R2 or p53R2). The 45-kDa subunits harbor diferric iron centers stabilizing tyrosyl free radicals crucial for catalytic activity (1) (2) (3) . Transcription of both RNR-R1 and RNR-R2 increases in S phase of the cell cycle (4-7). While RNR-R1 is stable throughout the cell cycle, RNR-R2 is abruptly degraded in late mitosis by the anaphase-promoting complex Cdh1/APC (6-9). p53R2 is a DNA damage response protein with both transcription and activity regulated by p53 (6) (7) (8) (9) .
Whether cellular responses to DNA damage increase RNR activity for de novo production of dNDPs remains controversial. Sources of dNDPs after DNA-damaging insults include intracellular dNDP pools, kinase-dependent salvage of deoxyribonucleosides, and reduction of intracellular ribonucleosides (7, 10) . Quiescent cells, and adriamycin-or radiation-treated cells activate ribonucleoside reduction first through a p53R2-mediated process first and subsequently through a complementary RNR-R2 mechanism (7, 11, 12) . Initial p53R2-mediated RNR activity is stimulated after DNA damage by activation of the tumor suppressor protein p53, a downstream target of the ATM/ATR Chk1/Chk2 kinase pathway (13, 14) .
Cervical cancer cells expressing mutant p53 and virally inhibited p53 show rapid rises in dNDP levels after exposure to ionizing radiation. This DNA damage response can be substantially blocked by administration of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), an RNR inhibitor currently under investigation in clinical trials (15) . Cervical cancer cells exposed to radiation plus 3-AP undergo G 1 -phase cell cycle arrest and have sustained radiation-induced DNA damage resulting in enhanced radiosensitivity (15) . Further support for the importance of RNR in DNA damage responses is provided by the observation that RNR-R2 and p53R2 overexpression confers resistance to ionizing radiation (16, 17) .
In this study, we investigate whether ionizing radiation-and cisplatin-induced DNA damage leads to elevated RNR activity in cervical cancer cells and whether the RNR inhibitor 3-AP increases both radiation and chemotherapy sensitivity through a mechanism of blocking RNR activity resulting in sustained DNA damage.
MATERIALS AND METHODS

Cell Cultures and Chemicals
Two cervical cancer cell lines were used: HPV-16-positive, wildtype-p53 CaSki cells (18) and HPV-naïve, mutated p53 (mut-p53, codon 273 Arg-Cys) C33-a cells (19) . Both human tumor cell lines were obtained from American Type Culture Collection (Rockville, MD) and maintained for culture at 37uC in a humidified 95% air/5% CO 2 atmosphere. The incubation medium for CaSki cells included RPMI 1640 medium supplemented with 10% fetal bovine serum, Lglutamine and 1% penicillin/streptomycin. Incubation medium for C33-a cells consisted of Eagle's minimum essential medium supplemented with 10% fetal bovine serum, sodium bicarbonate, 1 mM sodium pyruvate, and 1% nonessential amino acids.
Chemicals used were purchased from Sigma (St. Louis, MO) unless otherwise specified. 3-AP (NSC #663249) is an investigational agent supplied to Case Western Reserve University under an agreement with the National Cancer Institute Cancer Therapy Evaluation Program (NCI-CTEP, Bethesda, MD) and Vion Pharmaceuticals, Inc. (New Haven, CT). Ionizing radiation (0-10 Gy) was delivered using a 137 Cs c irradiator (J. L. Shepherd Associates, San Fernando, CA) at a dose rate of 3.33 Gy/min.
Clonogenic Survival Assays and Analyses of Radiation-Drug Interactions
Exponentially growing cells were plated on 60-mm dishes to yield 100 to 600 cells per dish. Cells received ionizing radiation (0-10 Gy) alone or in combination with a 6-h exposure to cisplatin (1-10 mM) and/or 3-AP (1-10 mM) as indicated and based on prior experiments with these agents. The human radiosensitizing in vivo doses of 3-AP and cisplatin are 5 mM (15, 20) . Colonies were fixed in 70% ethanol 14 days after plating and stained with 0.5% crystal violet, and surviving colonies (.50 cells) were counted. Surviving fractions were normalized using the plating efficiency of the untreated control.
Ribonucleotide Reductase Assays
Intracellular deoxycytidine triphosphate (dCTP) pools were quantified after irradiation (6 Gy) alone or in combination with 6-h cisplatin (5 mM) and/or 3-AP (5 mM) treatments using a DNA polymerase extension assay as described previously (15) . The nucleotide sequence for the DNA polymerase extension assay template was 59-AAA GAA AGA AAG AAA GAA AGG GCG GTG GAG GCG G-39 and the primer was 59-CCG CCT CCA CCG CC-39 (Integrated DNA Technologies, Coralville, IA). After a DNA polymerase extension reaction (15), a liquid scintillation counter quantified radioactivity with the 3 H-dTTP radioactivity incorporated linearly proportional to dCTP concentration up to 2.0 pmol.
Flow Cytometry for Cell Cycle Analysis and c-H2AX Staining
Exponentially growing cells (0.6-2.0 3 10 6 /100-mm dish) were treated with ionizing radiation (0-6 Gy) alone or in combination with 6 h exposure to cisplatin (1-10 mM) and/or 3-AP (1-10 mM), then fixed and stained for DNA content or c-H2AX as described previously (15) . Cells were stained with propidium iodide to measure DNA content or with mouse anti-human fluorescein isothiocyanate (FITC)-conjugated anti-c-H2AX antibody (Millipore, Billerica, MA) used at 1:500 dilution or 4 mg/ml to measure DNA damage foci. Cell immunofluorescence was measured with a Coulter EPICS XL-MCL flow cytometer (Beckman Coulter Inc., Miami, FL). Cell cycle analyses were done using ModFit LT 3.0 (Verity, Inc., Topsham, ME). The proportions of cells with c-H2AX immunofluorescence events brighter than control cells were counted using WinMDI 2.9 (The Scripps Research Institute, San Diego, CA).
Western Immunoblot and Laser Scanning Imaging Cytometry Analyses
Exponentially growing CaSki and C33-a cervical cancer cells (1.0 3 10 6 ) were treated with ionizing radiation (2 Gy), cisplatin (5 mM) and/ or 3-AP (5 mM). Western immunoblots were probed with mouse antihuman c-H2AX and rabbit anti-human p53R2 (Novus Biologicals, Littleton, CO), and rabbit anti-human p21 polyclonal (BD Transduction Laboratories, San Jose, CA) antibodies using established techniques (15) . Acquisition and analysis of images by laser scanning cytometry were done on cells plated on collagen-coated 24-well dishes using an inverted-type imaging cytometer (iCyte, Compucyte, Cambridge, MA). Formaldehyde-and methanol-fixed cells were blocked with 2% BSA/PBS (pH 7.2) for 5 min and then incubated with a 200-ml solution of p53R2 (1:100) and p21 (1:50) antibody for 1 h. After two 15-min washes with 2% BSA/PBS, cells were incubated with antirabbit Alexa Fluor 555 (p53R2, 1:100, Invitrogen, Carlsbad, CA), Alexa Fluor 647 (p21, 1:100, Invitrogen), and mouse anti-human FITC-conjugated c-H2AX (1 mg/well, Millipore, Temecula, CA) antibodies for 1 h. After two 15-min washes with 2% BSA/PBS, a DNA stain (diamidino-2-phenylindole, DAPI) was added. Twentyfour-well dishes with antibody-labeled cells were analyzed using an argon laser for green fluorescent c-H2AX (510 nm) and orange fluorescent p53R2 (580 nm), a violet diode laser for blue fluorescent DAPI (463nm), and a HeNe laser for red fluorescent p21 (650 nm). A 403 objective and 0.5-mm step size was used throughout, providing a field size of 500 3 192 mm and a pixel size of 0.5 3 0.25 mm and capturing 600-2,500 cells per well. Automated nuclear contours based on DAPI fluorescence signal (threshold and background correction applied) was used for p21 and c-H2AX quantification and for DNA content. Nuclear peripheral contours based on a width of 15 pixels from the nuclear contour were used for p53R2 quantification. Mean integral fluorescence per the manufacturer's instructions was measured in the nuclear contour for c-H2AX and p21 and in the peripheral nuclear contour for p53R2.
Statistical Methods
MANOVA statistics (a 5 0.05) using a balanced complete block factorial design were calculated for a global test for differences between ionizing radiation-drug dose responses, as we described previously for clonogenic survival assays (15, 21, 22) . RNR activity and c-H2AX assays used analysis of variance (ANOVA) or t tests of significance (a 5 0.05). Statistics were computed using SPSS Statistics software (version 12.0, Chicago, IL). For laser scanning imaging cytometry, three-way ANOVA stepwise regression and Pearson correlation coefficients (a 5 0.05) were calculated using the computational language/environment R (23).
RESULTS
Enhanced Chemoradiosensitization of Cervical Cancer Cells to Radiation, Cisplatin plus 3-AP Treatment
The effect of the RNR inhibitor 3-AP on ionizing radiation-and cisplatin-mediated DNA repair was investigated through analysis of H2AX phosphorylation at Ser-139 (c-H2AX) as a marker of DNA damage. The typical time to the peak c-H2AX signal is 1 h after ionizing radiation treatment and 6 h after a 2-h cisplatin RIBONUCLEOTIDE REDUCTASE CHEMORADIOSENSITIZATION 575 treatment (24, 25) . The loss of c-H2AX signal after the peak signal is an indicator of the extent of DNA damage repair, with a return to baseline levels observed 3 h after exposure to ionizing radiation and 12 h after cisplatin treatment (24, 25) . Addition of 3-AP to CaSki (Fig. 1a-x) or C33-a (Fig. 2a-x) cervical cancer cells exposed to ionizing radiation, cisplatin or a combination of both ionizing radiation and cisplatin caused a significant elevation in c-H2AX signal at 6 h after treatment. The addition of 3-AP to ionizing radiation caused an increase from 6% to 38% (P , 0.001) in CaSki cells and from 3% to 19% (P 5 0.001) in C33-a cells. Similarly, addition of 3-AP to cells treated with the combination of ionizing radiation plus cisplatin caused an increase from 30% to 66% (P , 0.001) in CaSki cells and from 26% to 47% (P , 0.001) in C33-a cells. Cells treated with 3-AP in addition to cisplatin showed a modest increase in c-H2AX levels from 17% to 28% (P 5 0.003) in CaSki cells and from 20% to 29% (P 5 0.025) in C33-a cells. Over the first 6 h after treatment, cells treated with ionizing radiation, cisplatin and 3-AP had significantly higher c-H2AX signal than one-or two-agent combinations, suggesting that 3-AP-mediated inhibition of RNR is responsible for sustained DNA damage (Figs. 1q-x and  2q-x) .
To relate the findings of a sustained c-H2AX signal to RNR blockade, intracellular dCTP levels were measured as a surrogate of RNR activity (15) . Six hours after 576 treatment, dCTP levels were increased in ionizing radiation-and cisplatin-treated cells compared to untreated cells, confirming that RNR activity is elevated after ionizing radiation-or cisplatin-induced DNA damage (P , 0.01; Figs. 1y, 2y ). The addition of 3-AP to cells treated with ionizing radiation and/or cisplatin led to a significant reduction in dCTP levels (P , 0.001). Taken together, these findings indicate that RNR may be critically responsible for the DNA damage-induced elevation of dNTP levels, and this induction can be repressed by administration of 3-AP.
Clonogenic survival was used to assess ionizing radiation and ionizing radiation-drug dose-effect relationships (Figs. 1z, 2z) . Moderate reductions in cell number were observed after 3-AP or cisplatin treatment alone. Using fixed doses of cisplatin (5 mM) and 3-AP (5 mM) and a range of 0-10 Gy ionizing radiation, substantial cell death was seen after ionizing radiation alone, with significant radiosensitization observed when cisplatin (P , 0.001) or 3-AP (5 mM, P , 0.001) was coadministered. The three-agent combination of ionizing radiation, cisplatin and 3-AP significantly enhanced radiosensitization compared to ionizing radiation (P , 0.001), ionizing radiation and 3-AP (P 5 0.001), or ionizing radiation and cisplatin (P 5 0.001).
We next examined combined treatments using fixed doses of ionizing radiation (2 Gy) and cisplatin (5 mM) with a range of 3-AP doses (0-10 mM). Cells were treated with RIBONUCLEOTIDE REDUCTASE CHEMORADIOSENSITIZATION ionizing radiation (0 or 2 Gy) followed by various concentrations of 3-AP ± cisplatin (5 mM) for 6 h. Figures 1zz and 2zz show the combined effects of both drugs and ionizing radiation. Both cervical cancer cell lines showed greater cytoreduction when ionizing radiation and cisplatin were added to 3-AP (P , 0.001 for both). These findings suggest that blockade of RNR activity by 3-AP, and thus de novo dNTP production, at the time of peak dNTP demand for repair of ionizing radiation or cisplatin damaged DNA significantly increases cell cytotoxicity.
DNA Damage is Associated with Increased p53R2 Protein
We showed previously that exponentially growing human cervical cancer cells arrest at the G 1 -phase transition of the cell cycle 18 h after exposure to 3-AP or ionizing radiation and 3-AP treatment (15) . To better define the temporal relationships between induction of p53R2, p21 and cell cycle behavior, CaSki and C33-a cells were treated with combinations of ionizing radiation, cisplatin and 3-AP. Cells were analyzed 6 h after treatment by laser scanning cytometry and Western blotting (Fig. 3) . c-H2AX staining indicated repair of DNA damage by 6 h after ionizing radiation and addition of 3-AP caused sustained DNA damage (i.e., persistent immunofluorescent c-H2AX foci) 6 h after ionizing radiation, cisplatin and 3-AP treatment (Fig. 3a ). An increase in cytoplasmic localization of p53R2 coincided with DNA damage, suggesting involvement of p53R2 in DNA repair (Fig. 3a) . In contrast, p21 immunoreactivity was unaltered or reduced with treatments (Fig. 3a) . When we analyzed cells after various treatments the relative intensity of c-H2AX staining corresponded to increases in p53R2 intensity (Fig. 3b ). Cells were monitored by flow cytometry at 6 h to determine the combinatorial effect of treatments on cell cycle phase distribution (Fig. 3c) . No consistent change in cell cycle phase distribution was detected after treatment. To corroborate our immunofluorescence intensity data, c-H2AX and p53R2 protein levels were monitored by Western blotting. Intensity of fluorescence by cytometry matched protein expression levels by Western blotting (Fig. 3b and d) . Collectively, these data indicate that protracted inhibition of RNR renders cells more susceptible to DNA-damaging agents and thus exacerbates the cytotoxicity of ionizing radiation and cisplatin.
DISCUSSION
Our data demonstrate that pharmacological inhibition of RNR by 3-AP enhances chemoradiation sensitivity through a mechanism involving sustained DNA damage. We find a synergistic ionizing radiationcisplatin-3-AP interaction on cytotoxicity but also a synergy when cisplatin and 3-AP were combined. These results imply that 3-AP-mediated inhibition of RNR activity impairs DNA damage repair processes that rely on dNTP production and promotes cell death.
Extracellular insults such as ionizing radiation and cisplatin induce clusters of damaged DNA bases, intraand interstrand DNA base crosslinks, and single-and double-strand DNA breaks. All are potentially lethal to cells (26) . Phosphorylation of histone -H2AX (c-H2AX) marks DNA damage within minutes (15, 24) . Of the many cellular responses to DNA damage, cells fix ionizing radiation-and cisplatin-induced DNA damage through nucleotide excision repair protein pathways. These pathways involve changes in DNA chromatin structure that are stabilized by c-H2AX. This action by c-H2AX allows endonucleases to excise damaged nucleotides and a limited number of adjacent undamaged nucleotides from DNA (27) . Undamaged nucleotides inserted into DNA for its repair may be salvaged from deoxyribonucleosides, may be withdrawn from intracellular pools, or may be synthesized de novo in a coordinated series of reactions in which the rate-limiting step is catalyzed by RNR (1-3). Our data support the hypothesis that ribonucleoside reduction is at least one critical source of dNTPs used in DNA repair, because DNA damage from ionizing radiation and/or cisplatin induces elevated RNR activity while inhibition of RNR by 3-AP perpetuates DNA damage (Figs. 1, 2) . It is therefore reasonable to suggest that the persistence of c-H2AX correlates with the extent of inhibition of repair of DNA damage and consequently with an increased chemoradiosensitivity and may prove to be a valuable predictive biomarker for DNA damage response in clinical specimens (25) .
It was somewhat surprising that p53R2 protein levels were elevated at 6 h after ionizing radiation and cisplatin treatment in G 1 -phase cervical cancer cells (Fig. 3) , because p53 induction of p53R2 transcription generally occurs over many hours and the cervical cancer cells used in these studies, like the vast majority of cervical tumors seen clinically, have defective p53 responses through either mutation of p53 (C33-a, p53 R273C) or the presence of HPV-16 E6 protein (CaSki). We now recognize that RNR is operative at very low levels under normal cellular conditions to provide dNTPs for repair of natural oxidative damage and depurination (7) . With DNA damage, RNR proteins levels are increased to more readily detectable levels (7, 15) . One possible explanation for altered p53R2 protein levels detected by immunofluorescence relies on the dual regulation of p53R2 by p53. For example, p53 is reported to bind p53R2 in a protein-protein interaction that inhibits p53R2?R1 association and subsequent reduction of ribonucleosides (9) . Ionizing radiation initiates a DNA response pathway involving ATM/ATR and Chk1/Chk2 proteins that phosphorylate p53 (13) , altering the p53?p53R2 protein-protein association. With RNR-R1 constitutively expressed throughout the cell cycle, func-578 tional RNR is generated when unbound p53R2 associates with RNR-R1. Perhaps to complement this rapid RNR response, p53-regulated transcription of p53R2 occurs as a secondary DNA damage response (3, 11) . Although other cellular mechanisms cannot be entirely excluded, our immunofluorescence data (Fig. 3) suggest that p53R2 levels increase rapidly after DNA damage.
One of the most significant findings in chemoradiosensitization with 3-AP treatment was the substantial reduction in RNR activity with concurrent ionizing radiation and/or cisplatin treatment. Ionizing radiation and/or cisplatin treatments elevated RNR activity resulting in higher levels of dCTPs detected in a PCRbased assay (Figs. 1, 2) . For ionizing radiation and/or FIG. 3 . DNA damage is associated with increased p53R2 expression 6 h after radiation or cisplatin treatment. Panel A illustrates laser scanning imaging cytometry of G 1 -phase CaSki cervical cancer cells 6 h after irradiation alone (2 Gy), after irradiation (2 Gy), 5 mM cisplatin plus 5 mM 3-AP treatment, and after no treatment. Nuclei are stained blue by DAPI, p53R2 stained yellow by rabbit anti-human p53R2?Alexa Fluor 555, p21 stained red by rabbit anti-human p21?Alexa Fluor 647, and DNA damage stained green by mouse anti-human FITC-conjugated c-H2AX antibodies. Dot plot depicts p53R2 intensity by DNA content (bar 5 mean of radiation-treated cells, arrow 5 cell depicted above in panel A). Sustained DNA damage at 6 h is associated with increased p53R2. Similar molecular results are found in C33-a cells (data not shown). Panel B depicts laser scanning imaging cytometry intensity (circles) of c-H2AX and p53R2 signal at 6 h after irradiation (2 Gy) and/or cisplatin (5 mM) and/or 3-AP (5 mM) as indicated. Triangles are mean intensity. A significant rise in p53R2 steady-state protein levels is observed after DNA damage. No change in p21 relative to control is detected (data not shown). Panel C illustrates that cell cycle distribution of exponentially growing cells has not been affected substantially 6 h after DNA damage. In panel D, C33-a cells were exposed to radiation (2 Gy) and/or cisplatin (5 mM) and/or 3-AP (5 mM) as indicated. Western blot (WB) antibodies show a moderate rise in c-H2AX protein 6 h after DNA damage. Compensatory rises in 6-h steady-state levels of p53R2 are apparent after DNA damage. No p21 protein was detected by Western blotting 6 h after DNA damage in CaSki or C33-a cells (data not shown).
RIBONUCLEOTIDE REDUCTASE CHEMORADIOSENSITIZATION cisplatin, 3-AP antagonized DNA repair and promoted cell death by reducing the extent of RNR dNTP production. However, 3-AP has an in vivo half-life of 2 h, with biologically active doses achieved for only 6 h after administration (17) . This would suggest that 3-AP should be administered shortly after ionizing radiation or cisplatin treatment to sustain damage caused in DNA. Such rationales were tested in our phase 1 clinical trial of daily radiation, once-weekly cisplatin chemotherapy, and three-times-weekly 3-AP (given after radiation or cisplatin chemotherapy) in advanced-stage cervical cancer patients. In this trial, substantial cervical cancer tumor responses without disease progression were achieved (17) .
Enhanced cytotoxicity was expected and observed in cervical cancer cells exposed to the RNR inhibitor 3-AP due to the inhibition of RNR at the time of DNA damage. Cervical cancer cells showed reduced RNR activity in the presence of 3-AP, persistence of DNA damage, and reduced cell survival. Impressive clinical responses to the combination of radiation, cisplatin and 3-AP have been observed in our recent phase 1 clinical trial in patients with advanced-stage cervical cancer (17) . A phase 2 clinical study at the Case Comprehensive Cancer Center (NCI-CTEP protocol 8327) continues to test the hypotheses that the RNR inhibitor 3-AP enhances radiation and chemotherapy sensitivity through a mechanism involving sustained DNA damage.
